DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dsspjt/tedatioxetine) has announced the addition of the "Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Tedatioxetine (Lu AA24530) is being developed by Lundbeck for the treatment of MDD. It is a multimodal antidepressant and preclinical studies have shown that it acts as a monoamine enhancer with reuptake inhibition at monoamine transporters, as well as a 5-HT3 and 5-HT2C receptor antagonist (Lundbeck, press release, July 2, 2009).
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tedatioxetine including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tedatioxetine for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Needs and Opportunities
7 Pipeline Assessment
8 Tedatioxetine (Lu AA24530)
For more information visit http://www.researchandmarkets.com/research/dsspjt/tedatioxetine